Previous Close | 1.4500 |
Open | 1.4500 |
Bid | 1.4200 x 2200 |
Ask | 1.4500 x 1400 |
Day's Range | 1.4158 - 1.4500 |
52 Week Range | 0.6010 - 7.0500 |
Volume | |
Avg. Volume | 372,486 |
Market Cap | 261.368M |
Beta (5Y Monthly) | 1.40 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.1660 |
Earnings Date | Aug 12, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
DUBLIN, Ireland and CHICAGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum Therapeutics”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has granted a non-statutory share option to purchase an aggregate of 2,500 ordinary shares of Iterum Therapeutics as an inducement to a newly hir
DUBLIN, Ireland and CHICAGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the United States Patent and Trademark Office (“USPTO”) has issued Iterum a Notice of Allowance for U.S. patent application number 16/372,075 en
--Patient Enrollment in Registration Trial for uUTI Underway-- --Cash Runway into 2024-- DUBLIN, Ireland and CHICAGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2022. “We are thri